Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

Withdrawn before enrolling · Not applicable

Conditions studied: Crohn's Disease

In brief

Crohn's disease is an inflammatory (swelling and soreness) disorder of the digestive tract. Affected patients suffer from abdominal pains, diarrhea (sometimes bloody), weight loss. It is a lifelong disease with frequent flares during the course of the disease. Crohn's disease is mostly treated with medications, sometimes surgery is needed. Infliximab is a medication for treating severe Crohn's disease. This medicine is effective by blocking special substance (tumor necrosis factor) released from certain white blood cells in the body. Infliximab is given via a vessel at week 0, 2, 6 initially, then every 2 monthly for maintenance. However, some of patients with Crohn's disease do not respond infliximab. Currently there is no test to reveal which patients will respond to treatment. This study aims to analyze and compare particular subgroup of white cells and its products during and after infliximab treatment which may determine the responsiveness to infliximab treatment.

Key facts

Study ID

NCT01266785

Run by

Oregon Health and Science University

People needed

0

Starts

2010-12-01

Expected to finish

2012-07-01

Last updated by the study team

2019-05-08

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed or exacerbating CD (Moderate to severe CD).
• The diagnosis of moderate to severe CD will be confirmed by previous endoscopy and biopsy.
• Have the capacity to understand and sign an informed consent form.

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.